公开(公告)号：US20240365665A1

公开(公告)日：2024-10-31

申请号：US18765825

申请日：2024-07-08

Applicant: Universal Display Corporation

Inventor： Hsiao-Fan Chen ,  Tongxiang (Aaron) Lu ,  Nicholas J. Thompson ,  Eric A. Margulies ,  George Fitzgerald ,  Jerald Feldman

IPC: H10K85/60 ,  C07D209/86 ,  C07D265/38 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D413/04 ,  C07D487/04 ,  C09K11/06 ,  H10K50/11 ,  H10K101/10

CPC classification number: H10K85/6572 ,  C07D209/86 ,  C07D265/38 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D413/04 ,  C07D487/04 ,  C09K11/06 ,  H10K85/615 ,  H10K85/622 ,  H10K85/623 ,  H10K85/624 ,  H10K85/626 ,  H10K85/631 ,  H10K85/633 ,  H10K85/636 ,  H10K85/654 ,  H10K85/657 ,  H10K85/6576 ,  C09K2211/1018 ,  H10K50/11 ,  H10K2101/10

Abstract: Compounds that are organic radicals that can have a dual function. The compounds can be fluorescent emitters that emit in the near-IR. The compounds can also facilitate reverse intersystem crossing (RISC) to convert triplet excitons in an OLED to singlet excited states to maximize utilization of generated excitons in the OLED and approach 100% internal quantum efficiency.

公开(公告)号：US20240352028A1

公开(公告)日：2024-10-24

申请号：US18416739

申请日：2024-01-18

Applicant: Araxes Pharma LLC

Inventor： Liansheng LI ,  Jun FENG ,  Tao WU ,  Pingda REN ,  Yi LIU ,  Yuan Liu ,  Yun Oliver Long

IPC: C07D495/04 ,  C07D215/46 ,  C07D215/54 ,  C07D217/22 ,  C07D239/84 ,  C07D239/94 ,  C07D239/95 ,  C07D241/44 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D409/04 ,  C07D487/04

CPC classification number: C07D495/04 ,  C07D215/46 ,  C07D215/54 ,  C07D217/22 ,  C07D239/84 ,  C07D239/94 ,  C07D239/95 ,  C07D241/44 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D409/04 ,  C07D487/04

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I):




or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

公开(公告)号：US20240336574A1

公开(公告)日：2024-10-10

申请号：US18280891

申请日：2022-03-10

Applicant: LATIGO BIOTHERAPEUTICS, INC. ,  LIEBER INSTITUTE, INC.

Inventor： Robert M. Jones ,  Ashok Bajji ,  Nathaniel Julius Thomas Monck ,  Suzanne J. O'Connor ,  William H. Gardiner ,  Robert James Townsend ,  Andreina Pacheco Pita ,  Michael Brunavs ,  Abdul Kadar Shaikh ,  Jonathan Paul Shine ,  Ian James Wigginton ,  Jonathan Philip Richards ,  Marco Michele Mastandrea ,  Adam James Davenport ,  Bryan Moyer ,  Michael Poslusney ,  James Barrow ,  Richard Edmund Rathmell

IPC: C07D237/24 ,  A61K31/455 ,  A61K31/4725 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D213/82 ,  C07D237/26 ,  C07D239/26 ,  C07D241/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

CPC classification number: C07D237/24 ,  A61K31/455 ,  A61K31/4725 ,  A61K31/50 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D213/82 ,  C07D237/26 ,  C07D239/26 ,  C07D241/24 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

Abstract: The invention provides methyl-substituted pyridine and pyridazine compounds, derivatives thereof, and methods of their use. The compounds are useful as pharmacological agents to treat a variety of conditions, including various pain states, itch, and cough.

公开(公告)号：US20240327402A1

公开(公告)日：2024-10-03

申请号：US18576252

申请日：2022-08-03

Applicant: ABBISKO THERAPEUTICS CO., LTD.

Inventor： Tao FENG ,  Baowei ZHAO ,  Mingming ZHANG ,  Shuqun YANG ,  Hongping YU ,  Zhui CHEN ,  Yaochang XU

IPC: C07D471/04 ,  A61K31/506 ,  A61P35/00 ,  C07D403/04 ,  C07D403/14 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61K31/506 ,  A61P35/00 ,  C07D403/04 ,  C07D403/14 ,  C07D519/00

Abstract: A pyrimidine or pyridine derivative having a structure represented by formula (I), a preparation method therefor, a pharmaceutical composition containing same, a use thereof as an EGFR inhibitor, and a use thereof in the preparation of a drug for treating and/or preventing cancer, tumors, or metastatic diseases associated at least in part with EGFR exon 20 insertions, deletions, or other mutations, especially a use thereof in the preparation of a drug for treating and/or preventing hyperproliferative diseases and the induction of cell death disorders.

公开(公告)号：US20240317757A1

公开(公告)日：2024-09-26

申请号：US18382727

申请日：2023-10-23

Applicant: Blueprint Medicines Corporation

Inventor： Brian L. Hodous ,  Joseph L. Kim ,  Kevin J. Wilson ,  Douglas Wilson ,  Yulian Zhang

IPC: C07D487/04 ,  A61K31/496 ,  A61K31/53 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D487/04 ,  A61K31/496 ,  A61K31/53 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D417/14

Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.

公开(公告)号：US12098144B2

公开(公告)日：2024-09-24

申请号：US18068902

申请日：2022-12-20

Applicant: Corcept Therapeutics Incorporated

Inventor： Mark Mills ,  Andrew William Phillips ,  Bohdan Waszkowycz ,  Hazel Joan Hunt ,  Angus Morrison ,  Angelo Pugliese ,  Jonathan Gillespie ,  Euan Fordyce

IPC: C07D403/14 ,  A61P43/00 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D403/14 ,  A61P43/00 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: Provided are piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.

公开(公告)号：US20240308983A1

公开(公告)日：2024-09-19

申请号：US18644412

申请日：2024-04-24

Applicant: Aptabio Therapeutics Inc.

Inventor： Soo Jin LEE ,  Sung Hwan MOON ,  Sooho BAN ,  Eunsil LEE ,  Eun Jung SHIN ,  Yoo-Kyung GOH

IPC: C07D401/14 ,  A61P1/16 ,  A61P11/00 ,  A61P35/00 ,  A61P39/06 ,  C07D231/54 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D495/04

CPC classification number: C07D401/14 ,  A61P1/16 ,  A61P11/00 ,  A61P35/00 ,  A61P39/06 ,  C07D231/54 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D495/04

Abstract: The Present invention provides a novel pyrazole derivative compound represented by Chemical formula 1, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same.




(In the above, A, B and R, and the like are the same as defined in the description of the invention.)

公开(公告)号：US12091401B2

公开(公告)日：2024-09-17

申请号：US16847534

申请日：2020-04-13

Applicant: WuHan TianMa Micro-electronics CO., LTD.

Inventor： Wenpeng Dai ,  Jinghua Niu ,  Wei Gao ,  Lei Zhang ,  Gaojun Huang

IPC: C07D403/04 ,  C07D239/26 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04 ,  C09K11/00 ,  H10K85/60

CPC classification number: C07D403/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  H10K85/653 ,  H10K85/654 ,  H10K85/6572 ,  H10K85/6574

Abstract: Provided are a nitrogen-heterocyclic compound, a display panel and a display apparatus. In an embodiment, the compound has a structure of Chemical Formula 1, in which X1 and X2 are each C or N, and at least one of X1 and X2 is N; X3 to X7 are N or —CRa, and one, two, three or four of X3 to X7 are N, where Ra is hydrogen, deuterium, a substituted or unsubstituted C1-C20 alkyl, C1-C20 alkoxy, C1-C20 thioalkyl, C6-C30 aryl, or C3-C30 heteroaryl; and Ra is independently present or forms an aliphatic ring, an aromatic ring, or a heteroaromatic ring with adjacent carbon atoms; Ar1 and Ar2 are each C6-C30 aryl or C3-C30 heteroaryl; and L1 and L2 are each a single bond, C6-C30 arylene, or C3-C30 heteroarylene. The compound is suitable as a CPL material to improve external quantum efficiency (EQE) of an organic light-emitting device and light-emitting efficiency.

公开(公告)号：US20240300963A1

公开(公告)日：2024-09-12

申请号：US18666084

申请日：2024-05-16

Applicant: Sun Pharmaceutical Industries, Inc.

Inventor： Robert S. LEWIS ,  Mahender Reddy KARLA ,  Kathryn E. KAVOURIS ,  Yong DONG ,  Adam J. MORGAN ,  Cameron J. COWDEN

IPC: C07D487/04 ,  C07B59/00 ,  C07C309/65 ,  C07D403/04

CPC classification number: C07D487/04 ,  C07B59/002 ,  C07C309/65 ,  C07D403/04

Abstract: Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed.

公开(公告)号：US20240299385A1

公开(公告)日：2024-09-12

申请号：US18561189

申请日：2022-06-03

Applicant: ReWind Therapeutics NV

Inventor： Vincent Pericolle ,  Jean-Christophe Vanherck ,  Arnaud Didier Marie Marchand ,  Guillaume Albert Jacques Duvey ,  Rui Miguel Garcia Costa Pinto

IPC: A61K31/506 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61P25/28 ,  C07D207/36 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

CPC classification number: A61K31/506 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61P25/28 ,  C07D207/36 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/06 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D471/04

Abstract: The present invention relates to a compound of formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a polymorph, a prodrug, an isotope, or a co-crystal thereof, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined in the description and claims. The present invention also relates to a pharmaceutical composition comprising a compound according to the invention, and a pharmaceutical acceptable carrier. The present invention also relates to the present compounds for use as a medicine and/or as diagnostics. The present invention also relates to the present compounds for use in the prevention and/or treatment of GPR17 mediated disorders, such as for example a disorder or syndrome selected from a myelination disorder and a disorder or syndrome associated with brain tissue damage.